Warnings and Precautions Not for type 1 diabetes or diabetic ketoacidosis Avoid in patients with history of medullary thyroid cancer or MEN 2 syndrome Caution in severe gastrointestinal disease or history of pancreatitis May delay absorption of oral medications Not recommended during pregnancy or breastfeeding Stay hydrated, especially during initial treatment Alternative Medications (by Indication) For type 2 diabetes or weight loss: Mounjaro (tirzepatide) dual GLP-1/GIP agonist Rybelsus (oral semaglutide) daily pill Trulicity (dulaglutide) weekly GLP-1 injection Victoza (liraglutide) daily GLP-1 injection Wegovy (semaglutide) higher-dose version for weight loss Metformin oral glucose control Insulin therapies for advanced cases Medication FAQs Ozempic (semaglutide) Is Ozempic insulin
Issue: Ophthalmologist unfamiliar or disapproving Common scenario: Most conventional ophthalmologists unfamiliar with peptide research, view as unproven experimental treatment, may discourage use out of caution or lack of knowledge
Effects of GLP-1 RAs on Promoting Somatostatin Release and Inhibiting Glucagon Secretion The effects of GLP-1 RAs on the release of somatostatin and the inhibition of glucagon secretion are complex and multifaceted
Published example listings: Earlier reporting on retatrutide pricing has highlighted very different online examples, including a 30 mg vial, a 20 mg vial, and even laboratory catalog pricing for much smaller quantities
doi: 10.3390/biomedicines9040383 46 LebrunLJLenaertsKKiersDPais de BarrosJPLe GuernNPlesnikJet al
For example, using glutathione for general antioxidant support is viewed differently than using it in high-dose intravenous (IV) forms for skin brightening, which many medical professionals advise against during pregnancy
